Bringing the Oncology Community Together

Dr. Jagannath on Life Expectancy in Myeloma

Sundar Jagannath, MD
Published Online: Tuesday, January 22, 2013
Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, details recent advances that have impacted the life expectancy of patients with multiple myeloma.

Fairly new drugs such as bortezomib, lenalidomide, dexamethasone, and thalidomide have moved life expectancy of all multiple myeloma patients from three years to five years, even for older patients. These drugs, Jagannath says, have also moved the life expectancy of younger, transplant-eligible patients from five to seven years.

As carfilzomib is being used more and pomalidomide is expected to be approved soon, Jagannath anticipates that all patients will live eight years and beyond. Elotuzumab and other drugs in the pipeline ( phase II clinical trials) could allow for multiple myeloma to be considered a chronic disease with 10-year survival and certain subsets able to be cured. As the populations of those subsets grow, Jagannath is hopeful that oncologists will be able to find the right drug and tailor patient therapy.

Related Articles
MSK's CAR Trials Halted Temporarily Amid Safety Review
Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia
Defining and Predicting Response to HMAs in MDS
In this segment, panelists discuss the lack of a clear connection between response to hypomethylating agents and molecular genetics as well as the larger role for cytogenetic assessment of response for patients with myelodysplastic syndrome.
Limited Availability of Non-Caucasian Stem Cell Donors: A Growing Problem?
To address the challenge of the limited availability of stem cell donors in non-Caucasians, it is vital that we increase awareness through more campaigns that are targeted specifically to minorities.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.